Media stories about Cambrex (NYSE:CBM) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cambrex earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.7852499852424 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Is this stock is Attractive? Cambrex Corporation (CBM) (nysestocks.review)
- Global Clozapine Market 2018 Abstract- Medichem, Shouguang Fukang Pharmaceutical, Cambrex and Novartis (businessservices24.com)
- Cambrex Corporation (CBM): Is this stock is more Volatile? (stockquote.review)
- Cambrex finishes pilot plant expansion in North Carolina (epmmagazine.com)
- Cambrex Expanding High Potency API Manufacturing Facilities In NC And Iowa (pharmaceuticalonline.com)
Several analysts have recently commented on CBM shares. Longbow Research cut Cambrex from a “buy” rating to a “neutral” rating in a report on Wednesday, February 14th. Zacks Investment Research cut Cambrex from a “hold” rating to a “sell” rating in a report on Tuesday, March 20th. Finally, ValuEngine cut Cambrex from a “hold” rating to a “sell” rating in a report on Thursday, May 3rd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $60.00.
NYSE CBM opened at $47.80 on Friday. Cambrex has a 1-year low of $42.55 and a 1-year high of $62.30. The company has a market capitalization of $1.58 billion, a P/E ratio of 15.08, a PEG ratio of 1.17 and a beta of 2.34.
Cambrex (NYSE:CBM) last released its quarterly earnings data on Thursday, May 3rd. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.22. Cambrex had a return on equity of 21.00% and a net margin of 18.69%. The firm had revenue of $141.10 million during the quarter, compared to the consensus estimate of $104.44 million. During the same period last year, the business posted $0.68 EPS. Cambrex’s quarterly revenue was up 34.4% on a year-over-year basis. equities analysts predict that Cambrex will post 2.73 earnings per share for the current fiscal year.
In related news, EVP Gregory Sargen sold 67,500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 8th. The stock was sold at an average price of $49.48, for a total value of $3,339,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Shawn Cavanagh sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 8th. The shares were sold at an average price of $49.69, for a total value of $1,987,600.00. The disclosure for this sale can be found here. Company insiders own 2.42% of the company’s stock.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.